BioSpace News Archive

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 7 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will participate in the Jefferies London Healthcare Conference in London, UK on Tuesday, November 15 at 3:50 PM GMT.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 7,200 restricted stock units of Atara’s common stock to two newly hired employees.

Insulet Corporation, announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers distributed globally.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 22,610 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.

IVERIC bio, Inc. announced that Iveric Bio management will participate in fireside chats at the following investor conferences in November.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.

Gelesis Holdings Inc. noted that the Company received a notification letter from the New York Stock Exchange advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual.

Precision BioSciences, Inc. announced that, on November 2, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.